Obesity-related complications included in the model were: T2D, myocardial infarction (MI), unstable angina, stroke and transient ischemic attack (TIA), sleep apnea, colon cancer, post-menopausal breast and post-menopausal endometrial cancers, and knee replacement surgery following osteoarthritis
Side Effects Across Different Dosage Levels Side effects typically intensify with each dose increase, though the pattern varies significantly between individuals: Starter Doses (Wegovy 0.25-0.5mg, Zepbound 2.5-5mg) Common: Mild nausea, reduced appetite, occasional constipation Less common: Mild heartburn, slight fatigue Rare at this stage: Severe vomiting, intense gastrointestinal distress Middle Doses (Wegovy 1-1.7mg, Zepbound 7.5-10mg) Common: Moderate nausea (often worse after meals), constipation, occasional vomiting, delayed gastric emptying (feeling full longer) Less common: Headaches, fatigue, sulfur burps, acid reflux Rare but reported: Hair thinning (typically temporary), gallbladder issues Maintenance Doses (Wegovy 2.4mg, Zepbound 12.5-15mg) Common: All of the above, potentially more pronounced Additional concerns: Muscle loss if protein intake isn't adequate Long-term considerations: Nutritional deficiencies due to reduced food intake, delayed gastric emptying Tolerance Development: Does the Effect Diminish Over Time
da Silva Serra, I., Husson, Z., Bartlett, J.D
Laboratory teams benefit from reduced customs delays, consistent packaging, and tracked delivery for predictable scheduling and workflow integration
